BenevolentAI S.A. (BAI.AS)
EUR 0.4
(-4.31%)
EUR 0.4
(-4.31%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 123.83 Million GBP | -33.41% |
| 2022 | 185.95 Million GBP | 100.63% |
| 2021 | 92.68 Million GBP | -37.42% |
| 2020 | 148.1 Million GBP | -2.26% |
| 2019 | 151.52 Million GBP | 68.51% |
| 2018 | 89.92 Million GBP | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q4 | 123.83 Million GBP | -16.62% |
| 2023 Q2 | 148.51 Million GBP | -20.14% |
| 2023 FY | 123.83 Million GBP | -33.41% |
| 2022 Q4 | 185.95 Million GBP | -18.22% |
| 2022 Q2 | 227.38 Million GBP | 145.33% |
| 2022 FY | 185.95 Million GBP | 100.63% |
| 2021 Q4 | 92.68 Million GBP | 0.0% |
| 2021 FY | 92.68 Million GBP | -37.42% |
| 2020 FY | 148.1 Million GBP | -2.26% |
| 2019 FY | 151.52 Million GBP | 68.51% |
| 2018 FY | 89.92 Million GBP | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -741.815% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 62.138% |
| Adocia SA | 24.95 Million EUR | -396.197% |
| Aelis Farma SA | 26.28 Million EUR | -371.181% |
| Biophytis S.A. | 11.93 Million EUR | -937.458% |
| Advicenne S.A. | 12.4 Million EUR | -898.074% |
| genOway Société anonyme | 31.84 Million EUR | -288.888% |
| IntegraGen SA | 8 Million EUR | -1447.82% |
| Medesis Pharma S.A. | 1.92 Million EUR | -6328.321% |
| Neovacs S.A. | 47.53 Million EUR | -160.513% |
| NFL Biosciences SA | 3.97 Million EUR | -3018.675% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -730.36% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -3205.006% |
| Sensorion SA | 46.49 Million EUR | -166.337% |
| Theranexus Société Anonyme | 7.23 Million EUR | -1610.908% |
| TME Pharma N.V. | 2.49 Million EUR | -4871.136% |
| Valbiotis SA | 33.24 Million EUR | -272.446% |
| TheraVet SA | 7.53 Million EUR | -1543.587% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -251.055% |
| argenx SE | 4.11 Billion EUR | 96.989% |
| BioSenic S.A. | 9.55 Million EUR | -1195.439% |
| Celyad Oncology SA | 16.28 Million EUR | -660.539% |
| DBV Technologies S.A. | 165.65 Million USD | 25.246% |
| Galapagos NV | 4.35 Billion EUR | 97.158% |
| Genfit S.A. | 173.87 Million EUR | 28.78% |
| GeNeuro SA | 6.31 Million EUR | -1861.555% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | -159.707% |
| Innate Pharma S.A. | 184.19 Million EUR | 32.771% |
| Inventiva S.A. | 69.13 Million EUR | -79.104% |
| MaaT Pharma SA | 42.93 Million EUR | -188.442% |
| MedinCell S.A. | 36.94 Million EUR | -235.149% |
| Nanobiotix S.A. | 93.89 Million EUR | -31.88% |
| Onward Medical N.V. | 43.62 Million EUR | -183.827% |
| Oryzon Genomics S.A. | 106.9 Million EUR | -15.838% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | -51.198% |
| Oxurion NV | 6.55 Million EUR | -1790.55% |
| Pharming Group N.V. | 426.33 Million EUR | 70.955% |
| Poxel S.A. | 4.82 Million EUR | -2467.51% |
| GenSight Biologics S.A. | 9.08 Million EUR | -1262.727% |
| Transgene SA | 45.21 Million EUR | -173.859% |
| Financière de Tubize SA | 1.92 Billion EUR | 93.551% |
| UCB SA | 15.53 Billion EUR | 99.203% |
| Valneva SE | 469.39 Million EUR | 73.619% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -301.671% |